rss
Br J Ophthalmol 2008;92:345-347 doi:10.1136/bjo.2007.121541
  • Original Article
    • Clinical science

Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial

  1. L B Cantor,
  2. D WuDunn,
  3. C W Yung,
  4. S Valluri,
  5. Y P Catoira,
  6. J S Hoop,
  7. L S Morgan
  1. Indiana University School of Medicine, Indianapolis, IN, USA
  1. L B Cantor, Department of Ophthalmology/Glaucoma Service, Indiana University School of Medicine, 702 Rotary Cir, Room 141, Indianapolis, IN 46202, USA; lcantor{at}iupui.edu
  • Accepted 9 September 2007
  • Published Online First 22 January 2008

Abstract

Background/aims: To compare the penetration of levofloxacin, ofloxacin and ciprofloxacin in the aqueous humour of eyes with functioning filtering blebs.

Methods: In this investigator-masked study, 48 patients with functioning filtering blebs requiring cataract surgery were randomised into six groups of eight patients. Groups 1, 2 and 3 received topical ofloxacin 0.3% (Ocuflox®), ciprofloxacin 0.3% (Ciloxan®) and levofloxacin (Quixin®) respectively; Groups 4, 5 and 6 received the same treatment with the corresponding oral dose of ofloxacin 400 mg (Floxin), ciprofloxacin 400 mg (Cipro) and levofloxacin 250 mg (Levaquin). Aqueous antibiotic levels were determined by mass spectrometry of aqueous samples from each patient.

Results: The mean aqueous level for topical levofloxacin was significantly higher than those achieved by topical ofloxacin or ciprofloxacin (p value = 0.02 and 0.01, respectively). The combination of topical and oral levofloxacin was significantly higher than topical levofloxacin alone (p = 0.05) and the ciprofloxacin combination (p = 0.003) but not significantly higher than the ofloxacin combination therapy.

Conclusions: Topical levofloxacin penetrates better than ofloxacin or ciprofloxacin into the aqueous of eyes with functioning filtering blebs. The combination of topical and oral levofloxacin may be preferable in the treatment of bleb-associated infections (NCT 00392275; Clinical trials.gov).

Footnotes

  • Funding: The work was in part supported by an unrestricted grant from Santen, Napa, California, USA.

  • Competing interests: None.

  • Patient consent: The study protocol and informed consent were approved by the appropriate Institutional Review Board; written informed consent was obtained from all enrolled patients and the study complied with the Declaration of Helsinki.

This Article

  1. All Versions of this Article:
    1. bjo.2007.121541v1
    2. 92/3/345 most recent

Services

  1. Request permissions

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.